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CD200 is a transmembrane protein that belongs to the immunoglobulin family of proteins and is ubiquitously
expressed on a variety of cell types. Upon interaction with its receptors (CD200Rs) expressed on myeloid-
derived cells and T lymphocytes, an immunoregulatory signal is delivered to receptor-expressing cells. Previous
studies have implicated a role for CD200:CD200R in the regulation of the expression of mRNA markers
of osteoclastogenesis/osteoblastogenesis, following interaction of CD200 (on osteoblast precursors) with
CD200R1 (on osteoclast precursors). Signaling of CD200R1 is hypothesized to attenuate osteoclastogenesis.
Wehave investigatedwhether levels of soluble forms of CD200 and/or CD200R1 (sCD200, sCD200R1) are altered
in volunteers undergoing 6° head down tilt bed rest tomimic conditions of microgravity known to be associated
with preferential osteoclastogenesis and whether countermeasures, reported to be beneﬁcial in attenuation of
bone loss under microgravity conditions, would lead to altered sCD200 and sCD200R1 levels. Our data suggest
that, as predicted, sCD200 levels fall under bed rest conditionswhile sCD200R1 levels rise. In subjects undergoing
30-minute per day continuous centrifugation protocols, as a countermeasure to attenuate changes which may
lead to bone loss, these alterations in sCD200 and sCD200R1 levels seen under conditions of bed rest were
abolished or attenuated. Our results suggest that measurement of sCD200 and/or sCD200R1 may prove a useful
and rapid means of monitoring subjects at risk of bone loss and/or accessing the efﬁcacy of treatment regimes
designed to counter bone loss.
© 2013 Elsevier Inc. All rights reserved.
Introduction
Amajor concern in health care is osteoporosis and bone loss. Immo-
bilization caused by injury (e.g. spinal cord injury, stroke etc. [1,2]),
as well as exposure to microgravity [3,4] reduces forces applied to
bone especially to weight bearing bones and leads to reduction of
bone mass.
6° head down tilt (HDT) bed rest is a commonly usedmodel to study
changes in many physiological systems, including changes in bone
mass, occurring during conditions of weightlessness such as in space
ﬂight [5,6]. During both bed rest and space ﬂight bone loss has been
documented,with the greatest changes noted inweight bearing skeletal
sites, such as the hip and pelvis, and with minimal changes in the wrist
or arm [4]. The mechanism behind this bone loss is thought to be the
uncoupling of bone remodeling, such that in microgravity bone resorp-
tion increases while bone formation remains unchanged or changes
very little. There are large variations in bone loss between individuals
and the sexes, implying that genetic variations are also important in
the regulation of bone mass [4,7].
Many countermeasures (exercise, nutrition, pharmaceuticals etc.)
have been tested for their efﬁcacy in preventing bone loss during either
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space ﬂight, or under bed rest conditions, with different success rates
[3,4]. Nutritional countermeasures tested so far have had either no [8]
or only very limited beneﬁts for bone. Flywheel resistive exercise and
pamidronate were only partially effective in preventing bone loss as
judged by changes in bonemineral density in the lower leg [9]. However
some exercise countermeasures have been shown to be more effective
and have some protective effect, including whole body vibration in
combination with resistive exercise [10,11], and treadmill exercising
in a lower body negative pressure (LBNP) chamber [12]. Combining
two different types of exercise, namely resistive (on a ﬂywheel) and
aerobic (with LBNP) exercises, helpedmitigate net bone loss by promot-
ing bone formation (but did not prevent bone resorption) [13].
Previous work from our lab showed that the interaction between the
ubiquitously expressed molecule CD200, and its receptor, CD200R1,
expressed on myeloid-cells, controls activation of cells of the monocyte/
macrophage lineage [14]. Osteoclasts express CD200R1, while osteoblast
precursors express the ligand, CD200 [15]. We hypothesized that CD200:
CD200R1 interactions suppress osteoclastogenesis, leaving osteoblasto-
genesis as the permissive pathway [16,17]. In a study conducted as part
of a spaceﬂight project (eOSTEO) [18], we showed that overexpression
of CD200 (using cell cultures derived from transgenic mice expressing
CD200 under control of a doxycycline-inducible promoter) under micro-
gravity conditions led to attenuation of the suppression ofmRNAmarkers
of osteoblastogenesis (bone sialoprotein and osteoprotegerin) normally
observed under such conditions. At the same time, in the presence of
increased CD200 expression, it was observed that the increase in expres-
sion of genes related to osteoclastogenesis (receptor activator of nuclear
factor kappa-B ligand (RANKL) and tartrate-resistant acid phosphatase),
which are normally seen in such microgravity conditions, was abolished
[18].
These observations led to our considering, as an auxiliary hypothesis,
that HDT bed rest with no countermeasures would be associated
with changes in levels of markers for bone homeostasis, namely CD200
and/or CD200R1. We have documented that both CD200 [19] and
CD200R1 (Kos and Gorczynski—unpublished) exist in normal serum in
soluble form (sCD200, sCD200R1). Both sCD200 and sCD200R indepen-
dently attenuate the signals (in ELISA/FACS) triggered by binding mAbs
to CD200 (or CD200R) to the cell membrane-expressed molecules.
Accordingly we reformulated our study to include assessment of wheth-
er bed rest would be associated with decreased levels of sCD200, and
increased levels of the soluble form of the receptor, sCD200R1, while
countermeasures to attenuate bone losswould lead to the reverse effects
on the levels of both of these two molecules.
In the present study, short term 6° head down tilt bed rest was used
with two different artiﬁcial gravity prescriptions (AG1: continuous
30 min centrifugation per day; and AG2: intermittent 6 × 5 min centri-
fugation daily) to assess their ability to attenuate markers of bone loss
induced by 5 days of bed rest. As surrogate markers for bone loss, we
monitored changes in: a serum marker of bone turnover, sRANKL,
beta CTX, sCD200 and sCD200R1; and markers of bone formation,
bone speciﬁc alkaline phosphatase (bALP) and propeptide of type I
Collagene (PINP). In urine, wemeasured changes in the collagen break-
down products DPD, NTX and CTX.
Methods
The short term bed rest (STBR) study was approved by the Comité
Consultatif de Protection des Personnes dans la Recherche Biomédicale,
Midi-Pyrenees (France), and the local ethics committees, including the
Ofﬁce of Research Ethics, University of Waterloo. The entire protocol
was performed in accordancewith the declaration of Helsinki. Each sub-
ject provided informed written consent before participation and was
aware of the right to withdraw from the study for any reason without
prejudice. The study itself was performed at the Institut de Médecine
et de Physiologie Spatiales (MEDES), Toulouse, France between April
and July 2010.
Subjects
12 healthy male volunteers agreed to participate in the study. The
mean age (±SD) was 32 ± 8 yr. The subjects had a mean height of
178 ± 8 cm, and weight 74.6 ± 7.8 kg. Only males were used in the
present study to avoid ﬂuctuations in bone metabolism known to
occur in cycling females [20–22].
Study design
The STBR study was designed as a randomized crossover trial with
one control- and two treatment groups (AG1 and AG2) with a 30 day
wash out period between, during which the subjects were released
from the facility. The subjects were randomly assigned to one of the
three groups in their ﬁrst campaign then to the other treatments in sub-
sequent campaigns. One participant fell ill midway through the control
period and was accordingly assigned to the control group during the
third campaign. Data from this subjectwas not included in the statistical
analysis. Each campaign consisted of a 5-day period of 6° head down tilt
(HDT) bed rest, with a 5-day data collection period before bed rest, and
a 5-day data collection period after bed rest. During the bed rest period
the subjects were conﬁned to strict 6° HDT bed rest.
Treatment
During the bed rest phase, control, AG1 and AG2 subjects were
transported daily on a 6°HDT gurney to the centrifuge facility, where
theywere transferred to the centrifuge arm (horizontal) andmonitored.
AG1 subjects were centrifuged continuously for 30 min at a force equiv-
alent to 1 g at the center of the mass, AG2 subjects received 6 × 5 min
centrifugation, and control subjects did not receive any centrifugation.
Some subjects did not tolerate continuous centrifugation well, and for
statistical analysis in the AG1 group only data from the 6 subjects who
completed the whole centrifugation protocol was included.
Because, the samplematerial was in limited supply, only 3 of those 6
subjects were used to assess their response to bed rest and applied
countermeasures using measurement of the concentration of collagen
breakdown products (namely βCTX) in their serum.
Biological sample collection and processing
Blood samples were collected ﬁrst thing in the morning; urine
samples were continuously collected throughout the day and pooled
for 24 h collection period. Table 1 lists the sample collection time points
with corresponding bone metabolism markers that were analyzed.
Table 1
Time points of biological sample collection and the corresponding bone metabolism
markers analyzed.
Time points of
sample collection
Bone marker analyzed in
Serum Urine
BDC-5 uNTx, uCTx, uDPD
BDC-4 sCD200, sCD200R1, sRANKL, βCTX , uNTx, uCTx, uDPD
BDC-3 sCD200, sCD200R1, sRANKL, βCTX,
Calcium,
uNTx, uCTx, uDPD
BDC-2 uNTx, uCTx, uDPD
BDC-1 bALP, PINP, uNTx, uCTx, uDPD
HDT1 uNTx, uCTx, uDPD
HDT2 uNTx, uCTx, uDPD
HDT3 sCD200, sCD200R1, sRANKL, βCTX, uNTx, uCTx, uDPD
HDT4 uNTx, uCTx, uDPD
HDT5 sCD200, sCD200R1, sRANKL, βCTX,
bALP, PINP,
uNTx, uCTx, uDPD
R + 1 sCD200, sCD200R1, sRANKL, βCTX, uNTx, uCTx, uDPD
R + 2 uNTx, uCTx, uDPD
R + 3 uNTx, uCTx, uDPD
R + 4 bALP, PINP, Calcium
R + 5
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Biochemical analysis
Blood
Blood samples were collected into the appropriate tubes and proc-
essed to yield serum.
The serum level of total sRANKLwasmeasured using a commercially
available ELISA from BioVendor-Laboratorní medicína a.s. (Brno, Czech
republic); for measurement of total human TNFα. A Platinum Sandwich
ELISA from eBioscience, Inc. (San Diego, CA) was used; the serum con-
centration of beta-Crosslaps (βCTX) was measured using a competitive
ELISA from Uscn Life sciences (Wuhan, P.R. China). Serum levels of
calcium were assayed at MEDES using ﬂame photometry method. The
basal level of bone speciﬁc alkaline phosphatase (bALP) was assessed
using Hybritech Tandem-R Ostase immunoradiometric assay (Liége,
Belgium). Procollagen-I-N-terminal propeptide (P1NP) levels in the
serum were measured using assay from Orion Diagnostica (Finland).
Intra- and Inter-Assay CVs for PINPwere 1.9% and 2.6% correspondingly.
Urine
To assess changes in the amount of collagen breakdown products
excreted by the body, daily urine collections were performed. Urine
was continuously collected on a void-by-void basis, kept in the dark
at 4 °C, and pooled in the laboratory for 24-h collection periods.
Daily urine volumes were measured and small aliquots were frozen at
−20 °C. Markers of bone resorption, C-Telopeptide (CTX) and N-
Telopeptide (NTX) were analyzed by commercially available assays
(NTX: Osteomark, TECOmedical, Bünde, Germany; CTX: Urine crosslaps,
IDS, Frankfurt, Germany) and deoxypyridinoline (DPD) was analyzed
by HPLC method. Intra-Assay CV for uCTX was 1.4% and Inter-Assay
CV—4.4%. Corresponding values for uNTXwere 1.4% and 4.9%. All results
were normalized against 24 h urine volume and are shown as excretion
rate per day. Excretion of urinary bone resorption markers are often
normalized against creatinine. However, since creatinine levels change
as a result of muscle breakdown, which is one of the hallmarks of bed
rest [23], and they also depend on nutrition, we opted to determine
the excretions of urinary markers as excretion rates per day and not to
normalize the values against creatinine.
Theonly creatinine values available to uswere serumcreatinine levels
measured 3 days before the start and4 days after the endof eachbed rest
campaign as shown in Supplementary Table 1. Interestingly, at the end of
the second campaign, increased creatinine levels of all participants were
seen independent of the applied countermeasures during this campaign,
whereas at the end of the ﬁrst and the third campaigns creatinine levels
did not change substantially from pre bed rest levels.
sCD200 ELISA
Levels of soluble CD200 in serum were measured using an ELISA
developed in our laboratory [19,24]. Monoclonal antibody 1B9 (rat
anti hCD200) was used as a capture reagent and polyclonal rabbit-
anti-human CD200 (V + C) serum was used as the detection antibody.
Somemodiﬁcations to the assay as initially described weremade to im-
prove sensitivity in this analysis. All serum samples were diluted 1:4 in
blocking buffer before analysis. In addition, the incubation time with
antigen and the incubation temperature were changed. Thus, plates to
which serum was added were incubated not for 2 h at room tempera-
ture, but overnight at 4 °C, followed by warming up at 37 °C for 1.5 h
on the following day. This addition of overnight incubation at 4 °C rather
than performing the complete assay within 1 day was found to improve
both sensitivity (approximately 3–5-fold) and reproducibility in the
assay (Kos and Gorczynski—unpublished). Intra-Assay CV was 4.6% and
Inter-Assay CV—6.9%.
sCD200R1 ELISA
Serum levels of the decoy receptor, sCD200R1, weremeasured using
a newly developed ELISA as follows. A high binding ELISA plate (Corning
Life Sciences) was coated with 100 ng (100 μL/well) of commercially
available anti-human CD200R1 antibody (R&D Systems, Inc.; Minneap-
olis, MN) and kept overnight at 4 °C. Following blocking for 1 h at RT
(200 μL blocking buffer/well, 5% FBS in PBS), serum samples, diluted
1:4 in blocking buffer, were added in duplicate and incubated at 4 °C
overnight. As a standard, a serial dilution of pure hCD200R1his protein
(a kind gift from Trillium Therapeutics Inc., Mississauga, Ontario) was
used at concentrations ranging from 7.8 to 250 pg/well. For detection
reagent, a 1:2000 dilution of polyclonal rabbit-anti hCD200R1 serum
was added to each well, with incubation for 1 h at 37 °C. This antibody
was raised against pure human CD200R1his protein, and it shows
no cross reactivity with CD200, either in ELISA (with CD200Fc) or on
Western Blot (with cell lysate of CD200 overexpressing HEK 293)
(see Supplementary Fig. 1). As secondary antibody, a goat anti-rabbit
IgG-HRP (Jackson ImmunoResearch Laboratories, Inc. West Grove, PA)
at 1:15,000 dilution was used (100 μL/well) with incubation for
45 min at 37 °C. At least 5 washes with wash buffer (PBS with 0.01%
Tween20) were performed between each step. Finally 100 μL of TBM
substrate (Thermo Fisher Scientiﬁc Pierce Protein Research, Rockford,
IL) was added for 15 min at 37 °C, with color development stopped by
addition of 50 μL of stop solution (0.2 M sulfuric acid). Absorbance
was read at 450 nm in a Multiskan Ascent 96/384 Plate reader (MTX
Lab Systems, Vienna, Austria). Intra- and Inter-assay CVs were deter-
mined to be 3.8% and 7.1% correspondingly.
However since all samples from one subject collected during one
campaign were analyzed on one ELISA plate, the analysis should not
affect the inter-assay CV.
Statistical analysis
The results for all sandwich ELISAs (sRANKL, sCD200, sCD200R1
and TNFα) were calculated applying a linear standard curve method.
βCTX data obtained using a competitive ELISA were calculated with a
5 point logistic curve created by MasterPlex ReaderFit software.
Statistical analyses were performed using GraphPad Prism software
(version 3.02) with the data in their original form. Changes in blood
levels of sCD200, sCD200R1, βCTX and sRANKL among all four phases
(pre bed rest (average of BDC results), head down tilt bed rest day 3
(HDT3), and day 5 (HDT5) and one day after bed rest (R + 1)) were
tested for statistical signiﬁcance using repeated measures analysis of
variance (ANOVA). Signiﬁcancewas assumedwhen p b 0.05. To analyze
differences from control values (measured before bed rest) and head
down tilt samples or post bed rest samples, Dunnett's multiple compari-
son tests were used. The samemethods were used for statistical analysis
of collagen breakdown product data, namely uNTX, uCTX and uDPD, as
well as both bone formation markers bALP and P1NP.
We elected not to use twowayANOVA,whichwould have allowed us
to take into account the day and time of the intervention in addition to
other variables, since we did not anticipate changes at early time points.
As an alternative we compared individual area under the curve (AUC)
values using a paired t test. This analysis revealed no statistical signiﬁ-
cance except for a trend observed (sCD200 levels) in AUC in AG1 cam-
paign compared to control campaign (p = 0.0554) (data not shown).
A paired t test was used to determine statistical signiﬁcance in serum
concentrations of Ca++before (BDC) and 4 days after (R + 4) bed rest.
Results
Graphic representations of the changes in serum levels for markers
of bone remodeling during the study are shown in Figs. 1–5 and Supple-
mentary Fig. 2. Some raw data are shown in Supplementary Tables 1–2.
Urine bone resorption markers uCTX, uNTX and uDPD
As seen in Fig. 1, under control conditions, the levels of all urine bone
resorption markers signiﬁcantly increased at day 4 of HDT bed rest
when compared to a corresponding averaged pre bed rest levels.
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Applied countermeasures were shown to have a relatively weak effect
in attenuating those increases. In fact, only increases in uDPDmeasured
under the control campaign at HDT4 (41.2%), were abolished by the ap-
plied artiﬁcial gravity protocols. In the case of uCTX and uNTX, counter-
measures were unable to mitigate those changes and in both the AG1
and AG2 campaigns, similar increases in urine levels of uCTX and
uNTX were measured during HDT bed rest.
Serum bone resorption marker βCTX
Levels of one of the collagen breakdown products (βCTX) measured
in serumwere elevated during the control and AG2 campaigns, with the
AG1 protocol more effective. As shown in Fig. 2, under control condi-
tions the levels of βCTX in the serum of the 3 subjects tested were in-
creased (mean 18.1%) by day 3 of bed rest, and remained elevated on
day 5. These increases became signiﬁcant only one day after the end
of bed rest (26.4%, p b 0.05). The same pattern was seen in the AG2
group, where the mean increase in βCTX level was 20% (p = 0.063) at
HDT3 and 23% (p = 0.093) at HDT5. One day after the end of bed rest
the 63% increase in βCTX reached statistical signiﬁcance (p b 0.05). In
a campaign where continuous centrifugation as a countermeasure was
applied, some minor but nonsigniﬁcant elevations in βCTX levels
(12.1% at HDT3 and 8.7% at HDT5) were detected, but at R + 1 the
levels fell close to the pre bed rest values.
sCD200R1
Both centrifugation protocolswere effective in attenuating changes in
sCD200R1 level. Even though countermeasures applied during this study
were unable to prevent the increases in sCD200R1 levels at the beginning
of bed rest (mean of 37.7% increase on day 3, p b 0.001 in AG1 and 40.5%
p b 0.05 in AG2), they did lead to normalization of sCD200R1 levels
more quickly than with subjects under control conditions and already
by day 5 of bed rest the levels of sCD200R1 were not signiﬁcantly differ-
ent from pre bed rest values (Fig. 3, and Supplementary Table 2). In
contrast, under control conditions the levels of sCD200R1 were signiﬁ-
cantly (p b 0.001) increased throughout bed rest (mean of 35.0% on
day 3 (p b 0.001) and 28.3% on day 5 (p b 0.05) of HDT) and remained
elevated one day after bed rest (30.3%, p b 0.001).
Comparing the changes in sCD200R1 and the urinary bone resorption
markers (uCTX and uNTX) occurring during bed rest (Supplementary
Figs. 2 and 3), it is clear that bed rest caused an increase in all those
markers. However, as indicated in Supplementary Fig. 2, where the X-
axis indicates the times at which sample collections were made, changes
in the levels of urinary bone resorptionmarkers occur at later times than
changes in the levels of sCD200R1. In Supplementary Fig. 3 the X-axis
shows levels of serum sCD200R1, and the ﬁgure compares changes
with changes in urinary bone resorption markers. In control and AG2
campaigns no statistically signiﬁcant correlations between thosemarkers
were found. In the AG1 campaign changes in sCD200R1 and uNTX were
found to be statistically signiﬁcant but changes between sCD200R1 and
the two others urinary bone resorption markers weren't. Given that
changes in urinary markers usually occur at the same time, the correla-
tion between sCD200R1 and uNTX may be more apparent than real.
sCD200
Serum levels of sCD200 (Fig. 3 and Supplementary Table 3)were sig-
niﬁcantly decreased during head down tilt bed rest. Under control con-
ditions, the sCD200 levels dropped approximately 25% below pre bed
Fig. 1. Percent changes in urine level of collagen type I C-Telopeptide (CTX), and N-Telopeptide (NTX) as well as deoxypyridinoline (DPD) during 5 days head down tilt bed rest study in
control and two countermeasure groups (AG1, AG2). Data are expressed as percent changes frompre bed rest calculated for each subject, withmean calculated for each group. *Signiﬁcant
difference as compared with pre bed rest; *p b 0.05, **p b 0.01, calculated using repeated measures analysis of variance (ANOVA) followed by Dunnett's test with data in their original
form. BDC—basal data collection; HDT3 and HDT5—head down Tilt bed rest days 3 and 5 accordingly; R + 1—one day of recovery.
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rest values (mean of 27.7%, p b 0.001 on day 3 and 22%, p b 0.001 on
day 5 of bed rest). After one day of recovery, CD200 levels still remained
signiﬁcantly lower (p b 0.001) compared to pre bed rest levels. Even
though levels of sCD200 at R + 1 showed some tendency to increase
when compared to levels measured at HDT3 and HDT5, those changes
were not statistically signiﬁcant, indicating that one day of recovery
was not sufﬁcient to attenuate changes induced by bed rest.
Countermeasures applied during this study had some effect on
attenuating decreases in sCD200 levels seen under control conditions
(Fig. 3). Continuous centrifugation, despite being not well tolerated,
produced a more marked effect in the subset (6) of subjects who com-
pleted all 5 days of the centrifugation protocol, with the decreases
in sCD200 levels frombaselineno longer signiﬁcant. Intermittent centri-
fugation was much better tolerated, but was not as effective at
preventing alterations to sCD200 levels. Thus, the decreases in sCD200
levels were signiﬁcantly lower on day 3 of head down tilt bed rest
(19.8%, p b 0.001) and after bed rest (17.2%, p b 0.05) in this group,
although changes in sCD200 levels on day 5 of bed rest were no longer
signiﬁcant.
Bone formation markers: bone speciﬁc bALP and PINP
Under control condition a signiﬁcantly increased level of bALP
was detected at HDT5 (16.9%, p b 0.001) (Fig. 4). Under the AG1
condition, a 25.6% increase in bone speciﬁc ALP was detected at HDT5
(p b 0.001), and a 27.6% increase at R + 4 (p b 0.001). In the intermit-
tent centrifugation campaign, the level of bALP rose at HDT5 9.6% in
comparison to BDC.
As seen in Fig. 4, serum levels for amarker for bone formation– PINP–
did not change signiﬁcantly either under control or AG1 andAG2 bed rest
conditions. Unfortunately, the samples formeasurement of sCD200, bALP
and P1NP were collected at different time points and we were unable to
perform a correlational analysis.
sRANKL, TNFα
Relative changes in the levels of sRANKL are shown in Fig. 5.
Headdownbed rest did not induce any signiﬁcant changes in thismarker
of bone remodeling and inﬂammation. TNFα was not detectable in the
serum of any of the 11 subjects that participated in the bed rest study
(the limit of detection in this assay was 5.0 pg/mL).
Calcium
Calcium levels (Supplementary Fig. 4) were signiﬁcantly elevated
4 days after the end of the control and both countermeasure campaigns,
when compared with corresponding pre bed rest values, measured
3 days before the start of each bed rest.
Fig. 2.Percent changes in serum level of betaCTXduring5 daysheaddown tilt bed rest study in control and two countermeasure groups (AG1, AG2). Data are expressed as percent changes
from pre bed rest calculated for each subject, with mean calculated for each group. *Signiﬁcant difference as compared with pre bed rest; *p b 0.05, calculated using repeated measures
analysis of variance (ANOVA) followed by Dunnett's test with data in their original form. BDC—basal data collection; HDT3 and HDT5—head down Tilt bed rest days 3 and 5 accordingly;
R + 1—one day of recovery.
Fig. 3. Percent changes in serum level of sCD200 and sCD200R1 during 5 days head down tilt bed rest study in control and two countermeasure groups (AG1, AG2). Data are expressed as
percent changes frompre bed rest calculated for each subject, with mean calculated for each group. *Signiﬁcant difference as compared with pre bed rest; *p b 0.05, **p b 0.01, calculated
using repeated measures analysis of variance (ANOVA) followed by Dunnett's test with data in their original form. BDC—basal data collection; HDT3 and HDT5—head down Tilt bed rest
days 3 and 5 accordingly; R + 1—one day of recovery.
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Discussion
A 6° head down tilt bed rest study is a useful and reliable simulation
model to characterize the physiological effects of space ﬂight [5]. Grav-
itational forces on the longitudinal skeleton are 83% less under bed rest
than in the upright, loaded position [25]. Bone adapts to mechanical
stimuli and reduction or absence of the latter leads to bone loss, primar-
ily through a sustained increase in bone resorptionwithmore subtle de-
creases in bone formation [12,26–29]. Weightlessness causes not only a
loss of bone density but also a decrease in muscle mass and red blood
cells, cardiovascular and sensory-motor deconditioning, and changes
in the immune system [6]. Artiﬁcial gravity, since it simulates the natu-
ral 1-g environment, would challenge all systems of the body (bone,
muscle, cardiovascular and vestibular systems) andwould be predicted
to be the ideal countermeasure [30].
The present studyhas evaluated the role of sCD200:sCD200R1 asmet-
abolic markers of bone homeostasis. CD200, a ubiquitously expressed
transmembrane protein with known immunoregulatory properties can
regulate the expression of genes involved in osteoclastogenesis and
osteoblastogenesis [17,18]. This regulation is thought to occur through
an interaction of CD200 (on osteoblasts) with its receptor CD200R1,
expressed on osteoclast precursors [15]. The cell surface availability of
many important receptor/ligand pairs involved in bone development,
including RANKL [31–33], RANK [34], CSF-1 [35,36], CSF-1R [37], is regu-
lated, at least in part, by ectodomain shedding, andwe recently described
a soluble variant of CD200 (sCD200) in the serum of healthy individuals,
likely present in the serum following a process of ectodomain shedding
[38], with demonstrable functional activity, binding and phosphorylating
CD200R1 [24].
Since the interaction of CD200with its cell bound receptor CD200R1
delivers an inhibitory signal for osteoclastogenesis, its level in the serum
of bed rest participants under control conditions was predicted to
decrease, in keeping with the increased bone resorption seen under
these conditions. The prediction was that under bed rest conditions
without countermeasures the serum levels of sCD200R1 would
increase. The short term bed rest study described abovewas the ﬁrst at-
tempt to measure simultaneously changes in these molecules under
conditions of reduced skeletal loading.
It is nevertheless important to acknowledge that one limitation of
the current study is that direct measurements of bone mass over the
5-day experimental study period were not performed in this analysis.
All measures used in the study described are surrogate markers of bone
loss, some of which (as noted below) have been accepted as such inmul-
tiple previous studies fromother groups. Our own subsequent analyses of
changes in levels of sCD200 and sCD200R1 have, in turn, been correlated
with alterations in these other surrogate markers, but have not been
directly correlated with alterations in bone mass per se.
Consistent with the hypothesis, we observed by day 3 of head
down bed rest that the levels of sCD200 were signiﬁcantly decreased
and those for sCD200R1 were increased in comparison to pre bed rest
Fig. 4. Percent changes in serum level of bone speciﬁc Alkaline phosphatase (bALP) andprocollagen-I-N-terminal propeptide (P1NP) during 5 days headdown tilt bed rest study in control
and two countermeasure groups (AG1, AG2). Data are expressed as percent changes from pre bed rest calculated for each subject, with mean calculated for each group. *Signiﬁcant
difference as compared with pre bed rest; *p b 0.05, **p b 0.01, ***p b 0.001, calculated using repeated measures analysis of variance (ANOVA) followed by Dunnett's test with data in
their original form. BDC—basal data collection; HDT3 and HDT5—head down Tilt bed rest days 3 and 5 accordingly; R + 1—one day of recovery.
Fig. 5.Percent changes in serum level of sRANKLduring 5 daysheaddown tilt bed rest study in control and two countermeasure groups (AG1, AG2). Data are expressed as percent changes
from pre bed rest calculated for each subject, with mean calculated for each group. * Signiﬁcant difference as compared with pre bed rest; *p b 0.05, calculated using repeated measures
analysis of variance (ANOVA) followed by Dunnett's test with data in their original form. BDC—basal data collection; HDT3 and HDT5—head down Tilt bed rest days 3 and 5 accordingly;
R + 1—one day of recovery.
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values. Since the levels of sCD200 and sCD200R1 change during bed rest
in opposite directions, this may be taken to imply that the molecules
regulating shedding release of these two proteins is/are not the same
entities.
We used two centrifugation protocols AG1 (continuous centrifuga-
tion for 30 min/day) and AG2 (intermittent centrifugation 6 × 5 min)
as countermeasures and compared them with each other and with a
control group to assess their effectiveness in preventing/attenuating
the changes described which we suggest predict bone loss associated
with disuse. Both artiﬁcial gravity protocols mitigated against the in-
creases in sCD200R1 levels seen with bed rest under control condition,
and already at day 5 of HDT changes in sCD200R1 were insigniﬁcant
when compared with pre bed rest levels. In the case of sCD200, the
AG2 protocol appeared to be less effective, with signiﬁcant increases
in sCD200 levels still measured at day 3 of HDT and at R + 1. In contrast,
AG1, while not as well tolerated, produced superior attenuation of the
decreases in sCD200 levels detected under control conditions. The
βCTX and bALP results also point towards the conclusion that continu-
ous centrifugation was a superior countermeasure in this study. In all
cases, we observed large variations between subjects, which are per-
haps not surprising since bone mechanosensitivity has a signiﬁcant
genetic component [39,40]. As an example of the latter, experiments
in C3H/Hemice showed signiﬁcantly less responsiveness to mechanical
loading than when two other mouse strains were tested (C57BL/6 and
DBA/2) [41].
Changes in bone turnover are reported to occur rapidly under bed rest
conditions, with increases in levels of bone resorptionmarkers, including
N-Telopeptide of type I collagen and type I collagen carboxytelopeptide,
indicative of enhanced osteoclast activity, by the 2nd day of immobiliza-
tion [26,42]. Bone formation markers were not inﬂuenced by short term
immobilization in the same study [26,42]. The levels of sCD200 and
sCD200R1, which we hypothesize are mediators of bone remodeling,
were predicted to precede any changes in bone resorption markers. We
measured serum levels for carboxy-terminal cross-linking telopeptide
of type I collagen (βCTX), which is generated by osteoclastic hydrolysis
of collagen I by cathepsin K [43], and recommended by the International
Osteoporosis Foundation and the International Federation of Clinical
Chemistry and Laboratory Medicine for use as a reference marker for
bone turnover in clinical studies [43,44]. The level of this bone resorption
marker has been found to be signiﬁcantly different between osteoporotic
and osteopetrotic patients [45] and it also has been shown to have a
greater utility for assessing efﬁcacy of antiresorptive treatment than
some previously described markers [46].
Changes in levels of sCD200R1 and particularly sCD200 levels did
indeed precede changes seen in βCTX. Thus sCD200 was signiﬁcantly
decreased by day 3 of HDT bed rest in both the control and AG2 groups,
and did not signiﬁcantly change in the AG1 group. Similarly βCTX was
increased in serum one day after the end of bed rest in the control and
AG2 groups, with no appreciable changes in theAG1 group. The changes
measured inβCTX on day 3 of HDT bed rest are similar to those reported
by Baecker et al. andHeer et al. [26,42], although in our study the chang-
es were not signiﬁcant, perhaps because of the smaller sample size
(n = 3).
The levels of all three collagen breakdown products measured in
urine (uCTX, uNTX and uDPD) also increased during HDT bed rest
under the control condition to an extent similar to those reported by
others [13,42]. Only uDPDwas affected by the applied countermeasures,
and its level was not signiﬁcantly elevated during bed rest in AG1 and
AG2 campaigns. The increase in uCTX and uNTX was not modulated
signiﬁcantly by any applied artiﬁcial gravity protocols.
RANK, RANKL and OPG, are acknowledgedmediators of osteoclasto-
genesis. Extreme skeletal phenotypes (osteoporosis vs. osteopetrosis) in
mice are associated with altered expression of these molecules [47].
Denosumab (a humanmonoclonal antibody to RANKL, which directly in-
hibits the RANKL/RANK signaling pathway) is an effective antiresorptive
agent used for treatment of postmenstrual osteoporosis [48,49]. In
contrast to the changes in the levels of CD200 and CD200R1, the levels
of sRANKL did not change signiﬁcantly under control conditions in the
course of our short term bed rest study. Measurements of free sRANKL
were analyzed in a previous bed rest study, but concentrations were
below the detection limit of the assay formost subjects [50].We have an-
alyzed total sRANKL level and observed amore rapid decrease in sRANKL
level at R + 1 when AG1 was applied as countermeasure. Moderate
changes in sRANKL during all three campaigns were observed, although
only for AG1was the change signiﬁcant, perhaps reﬂecting a homeostatic
return of the system to normal after effective stimulation.
Somewhat surprisingly, we observed an increase in the level of bone
speciﬁc ALP in the control campaign at day 5 of HDT bed rest, in contrast
to the results of Smith et al. [50]. However Kim et al. [51] observed sim-
ilar results in their 14 days bed rest study, namely an increase in bone
ALP level at the end of head down tilt. A marker of the later stages of
osteoblast differentiation (in the Kim et al. study it was osteocalcin, in
our study—PINP) did not change signiﬁcantly from pre bed rest level.
Applied continuous centrifugation seems to be able to induce bone
formation since the level of bone ALP at HDT5 and R + 4 was even
higher in the AG1 campaign than in the control one. Other countermea-
sures tested in different bed rest studies also showed similar results: re-
sistance exercise [52]; a combination of resistive and aerobic exercises
[13]; and resistive vibration exercise [53] all led to increased bALP levels
when compared to pre bed rest or control group.
Although the current short-duration study did not employ direct
measurements of bone loss to conﬁrm the impact of changes in
sCD200 and sCD200R1, our data strongly suggest that incorporation of
measurements of sCD200, sCD200R1 may provide useful, predictive in-
formation for those interested inmonitoring bone loss in humans under
different conditions. Future bed rest studies of longer duration are
planned with measurements of these plasma markers, as well as com-
puted tomographic analysis of bone composition to conﬁrm whether
sCD200 and sCD200R1 levels are valid surrogates for subsequent bone
alterations. In addition, it will be important to conduct parallel studies
with age-matched female participants in the bed rest studies to conﬁrm
whether regulation inmales and females is similar, orwhether hormon-
al inﬂuences can also modify the use of these surrogate markers.
Conclusion
Short term head down bed rest resulted in changes in the serum
markers, sCD200 and sCD200R1, that correlate with other markers
frequently associated with bone loss. Applied countermeasures (AG)
had a positive effect in attenuating the decline in sCD200 with an effect
also on sCD200R1. The data suggest that these markers may prove use-
ful in monitoring changes in bonemetabolism in such studies in future.
Our data further suggest that ﬁne tuning of the centrifugation proto-
col is likely required to optimize its impact. At least for sCD200, AG1
produced superior results as a countermeasure butwas notwell tolerat-
ed, with only 6 out of 11 subjects able to complete the required centri-
fugation. Introducing exercise with centrifugation might eliminate the
cardiovascular (hypotension) problems while maintaining the beneﬁts
for the skeletal system [54]. Taken together our data suggest that a
short term bed rest study may be a useful ﬁrst step for the develop-
ment/comparison of countermeasures to prevent bone loss associated
with disuse. They argue further that application of artiﬁcial gravity
may have a beneﬁcial effect in attenuating bone loss, as monitored by
the surrogate markers described.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bone.2013.12.004.
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